Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Epiminder Ltd. ( (AU:EPI) ) has issued an update.
Epiminder has reported its first quarterly update as a listed company following a $125 million IPO on the ASX, earmarked to commercialise its Minder epilepsy monitoring device. During the quarter, the company achieved a major clinical milestone with the first Minder implant in a US patient at the University of Pennsylvania as part of its DETECT study, signed five prominent US medical centres including three Mayo Clinic sites and Beth Israel Deaconess, and confirmed a higher‑than‑expected 2026 US Medicare reimbursement rate of about US$27,700 per procedure, supported by additional payments available under breakthrough device status. Financially, Epiminder ended the period with $89.5 million in cash and no debt, absorbed $32.7 million of one‑off costs including a lower‑than‑provisioned ATO R&D tax settlement that freed $4.2 million back into its commercialisation budget, and stated that existing cash should fund the DETECT study and further Minder development for the next two years as it focuses on accelerating US site and patient enrolment in the second half of FY26.
More about Epiminder Ltd.
Epiminder Limited (ASX: EPI) is a medical device company focused on breakthrough epilepsy monitoring technology. Its primary product, the FDA-approved Minder device, is a minimally invasive implant designed for continuous electrographic brain activity monitoring to help clinicians remotely assess and manage drug‑resistant epilepsy, including evaluating the effectiveness of therapies. The company is targeting leading medical centres, particularly in the United States, to integrate continuous EEG monitoring into standard epilepsy care.
Average Trading Volume: 212,747
See more data about EPI stock on TipRanks’ Stock Analysis page.